IDH1 and glioblastoma: A major prognostic metabolic marker researched throughout these studies is isocitrate dehydrogenase-1 (IDH1), which when correlated with various mutations of that marker, as well as when utilized for the characterization of patients, was found to be overexpressed in both high- and low-grade GBM patients [33,37,40].